RDD Pharma announces the receipt of a $1.28 million grant from the Department of Defense (DOD) to help enable US clinical development of RDD-0315 to help treat fecal incontinence in spinal cord ingury (SCI) patients.
The grant, from the DOD office of the Congressionally Directed Medical Research Programs (CDMRP), is funding the Spinal Cord Injury Research Program (SCIRP) Translational Research Award – Clinical Trial application.
The development of RDD-0315 includes preparations for and conducting of a Phase 1 study in healthy volunteers to assess acute tolerance and PK.
Positive Phase 2a results in Europe in evaluating the safety and efficacy of RDD-0315 for the treatment of fecal incontinence in spinal cord injury patients have previously been reported with a statistically significant reduction in the number of fecal incontinence episodes at 8 and 12 hours post-administration.
Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.
Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.
Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).
Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.